Apocynin, an NADPH oxidase inhibitor, suppresses rat prostate carcinogenesis. (Q39080681)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Apocynin, an NADPH oxidase inhibitor, suppresses rat prostate carcinogenesis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Kazuhide Shiraga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Shinya Sato

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Yoriko Yamashita

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Tomoyuki Shirai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Satoru Takahashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

28 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

1711-1717

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24118288%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

cites work

Global cancer statistics

1 reference

Extracellular adenosine triphosphate protects oxidative stress-induced increase of p21(WAF1/Cip1) and p27(Kip1) expression in primary cultured renal proximal tubule cells: role of PI3K and Akt signaling

21 January 2018

1 reference

The signaling mechanism of ROS in tumor progression

21 January 2018

1 reference

Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype

21 January 2018

1 reference

Oxidative stress in prostate cancer

21 January 2018

1 reference

The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology

21 January 2018

1 reference

Apocynin: molecular aptitudes

21 January 2018

1 reference

Effects of co-administration of dietary sodium arsenite and an NADPH oxidase inhibitor on the rat bladder epithelium.

21 January 2018

1 reference

Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment.

21 January 2018

1 reference

Purple corn color inhibition of prostate carcinogenesis by targeting cell growth pathways.

21 January 2018

1 reference

Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment

21 January 2018

1 reference

Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity

21 January 2018

1 reference

Increased oxidative stress in obesity and its impact on metabolic syndrome

21 January 2018

1 reference

Prostate cancer and adiponectin.

21 January 2018

1 reference

Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer

21 January 2018

1 reference

Gene ontology: tool for the unification of biology

21 January 2018

1 reference

The clusterin paradigm in prostate and breast carcinogenesis

21 January 2018

1 reference

Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer

21 January 2018

1 reference

Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control

21 January 2018

1 reference

SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation

21 January 2018

1 reference

Clusterin (CLU) and prostate cancer.

21 January 2018

1 reference

The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.

21 January 2018

1 reference

Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway

21 January 2018

1 reference

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation

21 January 2018

1 reference

Prostate cancer chemoprevention: current status and future prospects

21 January 2018

1 reference

Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

21 January 2018

1 reference

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

Apocynin, an NADPH oxidase inhibitor, suppresses progression of prostate cancer via Rac1 dephosphorylation.

21 January 2018

1 reference

Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol

21 January 2018

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model.

1 reference

PubMed

12 December 2020

Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent

1 reference

PubMed

12 December 2020